Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 4/2018

01-10-2018 | Gynecologic Endocrinology and Reproductive Medicine

Galectin-3 as a novel biomarker in women with PCOS

Authors: Gokce Anik Ilhan, Cansu Kanlioglu, Gaye Arslan, Begum Yildizhan, Tanju Pekin

Published in: Archives of Gynecology and Obstetrics | Issue 4/2018

Login to get access

Abstract

Purpose

This study aimed at evaluating galectin-3 levels as a novel metabolic biomarker in women with PCOS.

Methods

Ninety consecutive women with PCOS fulfilling the inclusion criteria were divided into two groups according to the presence of metabolic syndrome as MetS+ and MetS−. Clinical, hormonal, and metabolic parameters and galectin-3 levels were compared between the groups. Correlation analyses were performed between galectin-3 and clinical and metabolic parameters.

Results

Ninety PCOS subjects were enrolled in the study, 25 of which were diagnosed with MetS. Waist-to-hip ratio, systolic and diastolic blood pressures, triglyceride, HOMA-IR, FAI, FGS, and galectin-3 levels were significantly higher in the MetS+ group compared with the MetS− group (13.19 ± 5.63 vs 9.37 ± 3.99 ng/mL, respectively, p = 0.001). HDL cholesterol was significantly higher in the MetS− group than in the MetS+ one. Galectin-3 levels were found to be positively correlated with systolic blood pressure (r = 0.450, p < 0.01), diastolic blood pressure (r = 0.293, p < 0.01), and triglyceride levels (r = 0.218, p < 0.05) in women with PCOS.

Conclusions

Galectin-3 may be a promising novel biomarker in women with PCOS. Galectin-3 levels were significantly higher in the MetS+ group compared with the MetS− one and positively correlated with systolic, diastolic blood pressures and triglyceride levels in women with PCOS.
Literature
1.
Young DR, Hivert MF, Alhassan S et al (2016) Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the American Heart Association. Circulation 134(13):e262–e279CrossRefPubMed
2.
Grundy SM (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92(2):399–404CrossRefPubMed
3.
Dokras A, Bochner M, Hollinrake E et al (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106(1):131–137CrossRefPubMed
4.
Pugliese G, Iacobini C, Pesce CM et al (2015) Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 25(2):136–150CrossRefPubMed
5.
6.
Lisowska A, Knapp M, Tycińska A et al (2016) Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: a mid-term prospective cohort study. Atherosclerosis 246:309–317CrossRefPubMed
7.
Gehlken C, Suthahar N, Meijers WC et al (2018) Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin 14(1):75–92CrossRefPubMed
8.
Miró Ò, González de la Presa B, Herrero-Puente P et al (2017) The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure. Biomarkers 22(8):731–739CrossRefPubMed
9.
10.
Yilmaz H, Cakmak M, Inan O et al (2015) Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? J Endocrinol Investig 38(5):527–533CrossRef
11.
Orio F, Palomba S Jr, Cascella T et al (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:4588–4593CrossRefPubMed
12.
Orio F, Vuolo L, Palomba S et al (2008) Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 60(1):39–51PubMed
13.
Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnosis criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25CrossRef
14.
Hatch R, Rosenfield RL, Kim MH et al (1981) Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 140(7):815–830CrossRefPubMed
15.
Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMed
16.
Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome: a new worldwide definition. Lancet 366(9491):1059–1062CrossRefPubMed
17.
Yilmaz H, Celik HT, Ozdemir O et al (2014) Serum galectin-3 levels in women with PCOS. J Endocrinol Investig 37(2):181–187CrossRef
18.
19.
20.
Cuspidi C, Sala C, Provenzano F et al (2018) Metabolic syndrome and subclinical carotid damage: a meta-analysis from population-based studies. J Hypertens 36(1):23–30CrossRefPubMed
21.
22.
23.
Dong R, Zhang M, Hu Q et al (2018) Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. Int J Mol Med 41(2):599–614PubMed
24.
Filipe MD, Meijers WC, Rogier van der Velde A et al (2015) Galectin-3 and heart failure: prognosis, prediction and clinical utility. Clin Chim Acta 443:48–56CrossRefPubMed
25.
Agnello L, Bivona G, Lo Sasso B et al (2017) Galectin-3 in acute coronary syndrome. Clin Biochem 50(13–14):797–803CrossRefPubMed
26.
Ozturk D, Celik O, Satilmis S et al (2015) Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis 26(5):396–401CrossRefPubMed
27.
Caserta D, Adducchio G, Picchia S et al (2014) Metabolic syndrome and polycystic ovary syndrome: an intriguing overlapping. Gynecol Endocrinol 30(6):397–402CrossRefPubMed
28.
Essah PA, Wickham EP, Nestler JE (2007) The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 50(1):205–225CrossRefPubMed
Metadata
Title
Galectin-3 as a novel biomarker in women with PCOS
Authors
Gokce Anik Ilhan
Cansu Kanlioglu
Gaye Arslan
Begum Yildizhan
Tanju Pekin
Publication date
01-10-2018
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 4/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-018-4862-x

Other articles of this Issue 4/2018

Archives of Gynecology and Obstetrics 4/2018 Go to the issue

Gynecologic Endocrinology and Reproductive Medicine

The risk of birth defects among children born after vitrified blastocyst transfers and those born after fresh and vitrified cleavage-stage embryo transfers

Maternal-Fetal Medicine

Neonatal outcome in gestational-diabetic mothers treated with antenatal corticosteroids delivering at the late preterm and term

Gynecologic Oncology

Residual lesions in uterine specimens after loop electrosurgical excision procedure in patients with CIN

News and Views

Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: a “useless intraoperative fever” or the next hot voice in the surgical management of the “silent killer”?

Maternal-Fetal Medicine

Supplementation of folic acid in pregnancy and the risk of preeclampsia and gestational hypertension: a meta-analysis

Review

Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials